Sentiment amongst most holders is very positive and long so next real resistance level is a while off – most here have done their research and aren’t going anywhere but are in fact adding more to their positions.
The low volume sells last week is testament that all those accumulating are about to turn the tide and buyers will soon assume control again. Personally I think a market cap of 50 million prior to phase 2 is not unrealistic and is still trading under fair value for ALT1103 alone. Success during P2 should see a market cap 200 - 300 million regardless of market conditions… being successful after P2 and P3 will see a massive company born with potential up in to the billion dollar plus range. 2 years is not a long time to wait for these sorts of life changing gains.
In the meantime as T4P said it looks like the launch pad is about to be set by the trading we are all observing now. Results of P1 are due anytime within the next 8 weeks. After these results comes the confirmation of ALT1103s' graduation to P2. The company are aware of how ALT1103 will perform during P2 as they were trialling the drugs performance during P1, which is an overlap for what P2 is all about and for. So directors buying on market is a massive clue as to where they see this all heading, and reinforces their vision and confidence in this drug to current holders and the rest of the wider market.
Things are much different this time around… they have never bought their own stock on-market before, and they never released such bullish clues and statements either. ANP is entering a new area here… one that will see strong growth, and one that will demand and reap the respect of the big dollars and market players alike.
ANP has 3 quality drugs with 2 of them now entering advanced stages.. ALT1103 progress alone is worth 5 times the current market cap… in my experience these things rarely go unnoticed for too long. So should be very merry Xmas for all us current holders, as not too long to go now!!
IMO and Good Luck!
ANP Price at posting:
8.0¢ Sentiment: LT Buy Disclosure: Held
